Correlation of Pathologic Findings After Neo-Adjuvant Sorafenib With Results of Diffusion-Weighted Magnetic Resonance Imaging in Patients With Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2013
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 17 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 May 2012 Planned end date changed from 1 Jun 2013 to 1 Jun 2015 as reported by ClinicalTrials.gov.